{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:35:08Z","timestamp":1793928908543,"version":"4.8.0"},"reference-count":50,"publisher":"Informa UK Limited","issue":"4","license":[{"start":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T00:00:00Z","timestamp":1617408000000},"content-version":"unspecified","delay-in-days":47,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013650","name":"MorphoSys AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013650","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2021,4,3]]},"DOI":"10.1080\/14712598.2021.1884677","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T20:10:15Z","timestamp":1612901415000},"page":"455-463","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":44,"title":["Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma"],"prefix":"10.1080","volume":"21","author":[{"given":"Gilles","family":"Salles","sequence":"first","affiliation":[{"name":"Lymphoma Service, Memorial Sloan Kettering Cancer Center, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"D\u0142ugosz-Danecka","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Ghesqui\u00e8res","sequence":"additional","affiliation":[{"name":"H\u00e9matologie, Hospices Civils De Lyon and Universit\u00e9 De Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-019-01155-5"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2011.11.007"},{"key":"cit0003","unstructured":"Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975\u20132017, National Cancer Institute. Bethesda, MD, https:\/\/seer.cancer.gov\/csr\/1975_2017\/, based on November 2019 SEER data submission, posted to the SEER web site, April 2020"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25460"},{"key":"cit0006","unstructured":"NCCN. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: b-cell lymphomas [Internet]. 2020 [cited 2020 Jul 7]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf."},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv304"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-839217"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0752-3"},{"key":"cit0010","author":"Novartis Pharmaceuticals Corporation","journal-title":"Prescribing information. [Internet]"},{"key":"cit0011","author":"Kite Pharma Inc","journal-title":"Prescribing information. [Internet]Available from"},{"key":"cit0012","unstructured":"Bristol Myers Squibb. Bristol-Myers Squibb Announces Submission of Biologics License Application for CAR T-Cell Therapy Lisocabtagene Maraleucel (liso-cel) to FDA [Internet]. 2019. Available from: https:\/\/news.bms.com\/press-release\/corporatefinancial-news\/bristol-myers-squibb-announces-submission-biologics-license-ap. Access date 18.12.2019."},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0297-y"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3884"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2818"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018891598"},{"key":"cit0017","unstructured":"Karyopharm Therapeutics Inc. U.S. Food and Drug Administration Accepts Karyopharm\u2019s Supplemental New Drug Application for XPOVIO\u00ae (Selinexor) as a Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Internet]. 2020; [cited 2020 Jun 22]. Available from: https:\/\/investors.karyopharm.com\/node\/12646\/pdf."},{"key":"cit0018","unstructured":"Genentech I HIGHLIGHTS OF PRESCRIBING INFORMATION FULL PRESCRIBING INFORMATION: POLIVY\n                      TM\n                      (polatuzumab vedotin-piiq) [Internet]. 2019 [cited 2019 Jul 16]. Available from: www.fda.gov\/medwatch."},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-598763"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.1586"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651380"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0711"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601187"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg175"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01245"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1186\/2162-3619-1-36"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20030"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1080\/08820130500496878"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128511"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2268"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0508123103"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-593269"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-229039"},{"key":"cit0034","unstructured":"Boxhammer R, Striebel F, Baumgartner R, et al. Expression of CD19 antigen on chronic lymphocytic cells after tafasatamab (anti-CD19) treatment: phase 1 trial data (Abstract release date: 05\/14\/20) EHA Library. Boxhammer R. 06\/12\/20; 294589; EP671."},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124886"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy056"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.1528.1528"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124297"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30225-4"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128388"},{"key":"cit0041","unstructured":"Salles G, Duell J, Gonzalez-Barca E. et al. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. (Abstract release date: 05\/14\/20) EHA Library. Salles G. 06\/12\/20; 293691; EP1201."},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129371"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS7571"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8020"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.3429"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq626"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128021"},{"key":"cit0048","volume-title":"Prescribing Information","author":"MONJUVI","year":"2020"},{"key":"cit0049","unstructured":"MorphoSys AG. MorphoSys and Incyte Announce the Validation of the European Marketing Authorization Application for Tafasitamab. Media Release Planegg\/Munich, Germany [Internet]. May 20, 2020 Available from: https:\/\/www.morphosys.com\/media-investors\/media-center\/morphosys-and-incyte-announce-the-validation-of-the-european-marketing"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-130506"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2021.1884677","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T21:53:27Z","timestamp":1618610007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2021.1884677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4,3]]}},"alternative-id":["10.1080\/14712598.2021.1884677"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2021.1884677","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-09-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}